Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Factors For Malignant Pleural Mesothelioma

F. Brims, N. Maskell
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
The prognosis for patients with malignant pleural mesothelioma (MPM) is generally regarded as poor, although rare cases of long-term survivors are recognised. Previous prognostic scoring systems have been based on clinical trial populations and are not widely utilised. Population studies consistently confirm non-epithelioid histology, advanced age, and male gender as independent risk factors for poor outcome of MPM. Genetic and immunohistochemical studies continue to provide advances in tumour biology, but no clear validated prognostic factors have been identified to date. Nuclear mitotic and atypia grading systems may provide useful prognostic knowledge; further evaluation is needed. Such biomarkers as soluble mesothelin-related protein and osteopontin provide some prognostic information, though with limitations. The baseline serum neutrophil-to-lymphocyte ratio could also provide prognostic information. Modern metabolic imaging techniques, for example PET/CT, can indicate prognosis by use of baseline total glycolytic volumes (TGV). TGV may also be useful in identifying early responders to systemic chemotherapy treatment. Research to identify clinically useful prognostic factors in MPM remains a priority.
This paper references
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Rhian S Finn (2012)
Prognostic factors for mesothelioma.
J. Steele (2005)
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
J. Edwards (2003)
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
S. Cedrés (2012)
p27 immunostaining is related to prognosis in malignant mesothelioma
T. Beer (2001)
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
N. Hirayama (2011)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
Sustained Expression of Steroid Receptor Coactivator SRC-2/TIF-2 is Associated with Better Prognosis in Malignant Pleural Mesothelioma
C. Jennings (2012)
Post mortem findings of malignant pleural mesothelioma: a Two-Centre Study of 318 patients. Chest
RS Finn (2012)
Analysis of survival of mesothelioma cases in the Italian register ( ReNaM )
A Marinaccio (2003)
The serine protease HtrA1 is a novel prognostic factor for human mesothelioma.
A. Baldi (2008)
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
prediction of therapeutic response and prognostic implications
HY Lee (2013)
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
Sara Busacca (2010)
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
Prognosis and prognostic factors of patients with mesothelioma: a population-based study
S. van der Bij (2012)
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos (2006)
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
A. Yasumitsu (2010)
Using microRNAs to inform clinical decision making in lung cancer: ready for prime time?
Avrum Spira (2012)
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
Kyuichi Kadota (2012)
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma
S. Kao (2012)
Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register
V. Neumann (2004)
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
J. Fischer (2006)
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A. Baldi (2004)
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
J. Edwards (2006)
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
E. Pompeo (2009)
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
Prognostic value of 18 F - FDG PET / CT in patients with malignant pleural mesothelio
ST Lee (2009)
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Alexandra Schramm (2010)
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
J. Edwards (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
G. Pinton (2009)
Malignant Pleural Mesothelioma: A Population-Based Study of Survival
M. Milano (2010)
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelio
NJ Vogelzang (2003)
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
S. Nojiri (2011)
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
A. Marinaccio (2003)
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar